Cargando…
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
Multiple Myeloma (MM), a clonal malignancy of antibody-producing plasma cells, is the second most common hematologic malignancy and results in significant patient morbidity and mortality. The high degree of immune dysregulation in MM, including T cell imbalances and up-regulation of immunosuppressiv...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802552/ https://www.ncbi.nlm.nih.gov/pubmed/29208938 http://dx.doi.org/10.1038/s41408-017-0020-0 |
_version_ | 1783298542309212160 |
---|---|
author | Meyers, Daniel E. Thakur, Satbir Thirukkumaran, Chandini M. Morris, Don G. |
author_facet | Meyers, Daniel E. Thakur, Satbir Thirukkumaran, Chandini M. Morris, Don G. |
author_sort | Meyers, Daniel E. |
collection | PubMed |
description | Multiple Myeloma (MM), a clonal malignancy of antibody-producing plasma cells, is the second most common hematologic malignancy and results in significant patient morbidity and mortality. The high degree of immune dysregulation in MM, including T cell imbalances and up-regulation of immunosuppressive checkpoint proteins and myeloid derived suppressor cells, allows this malignancy to escape from host immune control. Despite advances in the therapeutic landscape of MM over the last decade, including the introduction of immunomodulatory drugs, the prognosis for this disease is poor, with less than 50% of patients surviving 5 years. Thus, novel treatment strategies are required. Oncolytic viruses (OV) are a promising new class of therapeutics that rely on tumour specific oncolysis and the generation of a potent adaptive anti-tumour immune response for efficacy. To date, a number of OV have shown efficacy in pre-clinical studies of MM with three reaching early phase clinical trials. OVs represent a rational therapeutic strategy for MM based on (1) their tumour tropism, (2) their ability to potentiate anti-tumour immunity and (3) their ability to be rationally combined with other immunotherapeutic agents to achieve a more robust clinical response. |
format | Online Article Text |
id | pubmed-5802552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58025522018-02-08 Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma Meyers, Daniel E. Thakur, Satbir Thirukkumaran, Chandini M. Morris, Don G. Blood Cancer J Review Article Multiple Myeloma (MM), a clonal malignancy of antibody-producing plasma cells, is the second most common hematologic malignancy and results in significant patient morbidity and mortality. The high degree of immune dysregulation in MM, including T cell imbalances and up-regulation of immunosuppressive checkpoint proteins and myeloid derived suppressor cells, allows this malignancy to escape from host immune control. Despite advances in the therapeutic landscape of MM over the last decade, including the introduction of immunomodulatory drugs, the prognosis for this disease is poor, with less than 50% of patients surviving 5 years. Thus, novel treatment strategies are required. Oncolytic viruses (OV) are a promising new class of therapeutics that rely on tumour specific oncolysis and the generation of a potent adaptive anti-tumour immune response for efficacy. To date, a number of OV have shown efficacy in pre-clinical studies of MM with three reaching early phase clinical trials. OVs represent a rational therapeutic strategy for MM based on (1) their tumour tropism, (2) their ability to potentiate anti-tumour immunity and (3) their ability to be rationally combined with other immunotherapeutic agents to achieve a more robust clinical response. Nature Publishing Group UK 2017-12-05 /pmc/articles/PMC5802552/ /pubmed/29208938 http://dx.doi.org/10.1038/s41408-017-0020-0 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Meyers, Daniel E. Thakur, Satbir Thirukkumaran, Chandini M. Morris, Don G. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
title | Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
title_full | Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
title_fullStr | Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
title_full_unstemmed | Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
title_short | Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
title_sort | oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802552/ https://www.ncbi.nlm.nih.gov/pubmed/29208938 http://dx.doi.org/10.1038/s41408-017-0020-0 |
work_keys_str_mv | AT meyersdaniele oncolyticvirotherapyasanimmunotherapeuticstrategyformultiplemyeloma AT thakursatbir oncolyticvirotherapyasanimmunotherapeuticstrategyformultiplemyeloma AT thirukkumaranchandinim oncolyticvirotherapyasanimmunotherapeuticstrategyformultiplemyeloma AT morrisdong oncolyticvirotherapyasanimmunotherapeuticstrategyformultiplemyeloma |